Abstract:Introduction: Porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis virus (TGEV) are major intestinal coronaviruses that cause vomiting, diarrhea, dehydration, and mortality in piglets. These viruses coexist and lead to significant economic losses in the swine industry. Virus-like particles (VLPs) have emerged as promising alternatives to conventional inactivated vaccines due to their exceptional safety, efficacy, and ability to provide multi-disease protection with a single dose. Methods: Our study focused on specific antigenic epitopes from the PEDV S protein (SS2 and 2C10 regions) and the TGEV S protein (A and D sites) as target candidates. These epitopes were integrated into the ADDomer framework, and we successfully generated recombinant proteins AD, AD-P, AD-T, and AD-PT using the baculovirus expression vector system (BEVS). By meticulously optimizing conditions in High Five cells, we successfully expressed and purified the recombinant proteins. Subsequently, we developed the recombinant ADDomer-VLP vaccine and conducted a comprehensive evaluation of its efficacy in piglets. Results: Following ultrafiltration concentration and sucrose gradient centrifugation purification, the recombinant proteins self-assembled into VLPs as observed by transmission electron microscopy (TEM). Administration of the vaccine did not result in any adverse reactions in the immunized piglets. Additionally, no significant instances of fever were detected in any of the experimental groups, and there were no notable changes in average daily weight gain compared to the control group that received PBS. The recombinant ADDomer-VLP vaccines demonstrated strong immunogenicity, effectively stimulating the production of neutralizing antibodies against both PEDV and TGEV. Moreover, the recombinant ADDomer-VLP vaccine induced elevated levels of IFN-γ, IL-2, and IL-4, and enhanced cytotoxic T lymphocyte (CTL) activity in the peripheral blood of piglets. Discussion: These recombinant VLPs have demonstrated the ability to induce strong cellular and humoral immune responses in piglets, making them an incredibly promising platform for the rapid and simplified development of epitope vaccines.

Immunogenicity of adenovirus-derived porcine parvovirus-like particles displaying B and T cell epitopes of foot-and-mouth disease

Immune Responses of Two Recombinant Adenoviruses Expressing VP1 Antigens of FMDV Fused with Porcine Granulocyte Macrophage Colony-Stimulating Factor

Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon α in mice and protective efficacy in guinea pigs and swine

Protection of Guinea Pigs and Swine by a Recombinant Adenovirus Expressing O Serotype of Foot-and-mouth Disease Virus Whole Capsid and 3C Protease.

Immune Responses of Recombinant Adenovirus Co-Expressing VP1 of Foot-and-mouth Disease Virus and Porcine Interferon Α in Mice and Guinea Pigs

Virus-like particles of recombinant PCV2b carrying FMDV-VP1 epitopes induce both anti-PCV and anti-FMDV antibody responses

Poly(I:C) Combined with Multi-Epitope Protein Vaccine Completely Protects Against Virulent Foot-and-mouth Disease Virus Challenge in Pigs

Construction of Recombinant Adenovirus Co-expressing VP1-2A of Foot and Mouth Disease Virus and Porcine IL-2 and Its Immune Effects

Enhancement of Mouse Immune Response by Recombinant Adenovirus Co-Expressing VP1-2A of Foot-and-mouth Disease Virus and Porcine IFN-α

Chimeric Porcine Parvovirus VP2 Virus-like Particles with Epitopes of South African Serotype 2 Foot-and-Mouth Disease Virus Elicits Specific Humoral and Cellular Responses in Mice

A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

Expression and immunogenicity of capsid protein of porcine circovirus type 2 with N-terminal chimeric neutralizing epitopes of foot-and-mouth disease virus

Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant.

Protection of a Novel Epitope-Rna VLP Double-Effective VLP Vaccine for Foot-and-mouth Disease.

Expression of Porcine parvovirus-like Particles Carrying a CSFV T Cell Epitope and Its Immunization on Mice

Porcine Parvovirus Capsid Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles with High Immunogenicity in Mice and Guinea Pigs.

Promising MS2 Mediated Virus-Like Particle Vaccine Against Foot-and-mouth Disease.

Virus-like particle vaccines with epitopes from porcine epidemic virus and transmissible gastroenteritis virus incorporated into self-assembling ADDomer platform provide clinical immune responses in piglets

Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs

Construction and Immunogenicity Evaluation of Recombinant Adenovirus-Expressing Capsid Protein of Foot-and-Mouth Disease Virus Types O and A

Expression and immunogenicity of recombinant fusion protein comprising foot-and-mouth disease virus structural protein VP1 and intercellular adhesion molecule ICAM-2